Squarepoint
XGN icon

Squarepoint’s Exagen XGN Stock Holding History

Squarepoint’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$866K Buy
288,825
+200,793
+228% +$777K ﹤0.01% 2905
2025
Q4 		$535K Buy
+88,032
New +$801K ﹤0.01% 3157
2021
Q1 		– Sell
-10,078
Closed -$133K – 3682
2020
Q4 		$133K Sell
10,078
-7,774
-44% -$110K ﹤0.01% 2650
2020
Q3 		$194K Buy
17,852
+3,997
+29% +$51.5K ﹤0.01% 2104
2020
Q2 		$172K Sell
13,855
-2,318
-14% -$31.4K ﹤0.01% 1869
2020
Q1 		$258K Buy
16,173
+909
+6% +$18K 0.01% 1367
2019
Q4 		$388K Buy
+15,264
New +$272K ﹤0.01% 1905

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Squarepoint's XGN Position: Q1 2026 in Review

Squarepoint increased its Exagen (XGN) stake by 228% in Q1 2026, buying an estimated $777K and bringing the position to 288,825 shares worth $866K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

Squarepoint first reported a position in XGN in Q4 2019 and has held it in 7 quarters since. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Squarepoint held 288,825 shares of Exagen worth $866K as of Q1 2026.
  • Squarepoint bought 200,793 Exagen shares in Q1 2026, an estimated $777K.
  • Exagen made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2905 holding.
  • Squarepoint first reported a position in Exagen in Q4 2019 and has held it in 7 quarters since.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.